A pharmaceutical combination comprising an EGFR inhibitor and an Hsp90 inhibitor according to the following formulaea tautomer, or a pharmaceutically acceptable salt thereof, wherein the variables in the structural formulae are defined herein. Also provided are methods for treating a proliferative disorder in a subject in need thereof using pharmaceutical combinations disclosed herein.
